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When to Start ART in Africa
To the Editor: In their Perspective article, De 
Cock and El-Sadr (March 7 issue)1 highlight the 
need for data on when to start antiretroviral ther-
apy (ART) for HIV-infected people in Africa who 
have CD4+ counts above 350 cells per cubic milli-
meter. However, their proposed solution — a new 
randomized, controlled trial in Africa — is flawed.
First, before a new randomized, controlled trial 
could commence in Africa, data from the Strategic 
Timing of Antiretroviral Treatment (START) 
trial (ClinicalTrials.gov number, NCT00867048), 
the Early Antiretroviral Treatment and/or Early 
Isoniazid Prophylaxis Against Tuberculosis in HIV-
Infected Adults (TEMPRANO) trial (NCT00495651), 
and the Evaluating Strategies to Reduce Mother-to-
Child Transmission of HIV Infection in Resource-
Limited Countries (PROMISE) trial (NCT01061151) 
will most likely disturb the equipoise that argu-
ably exists today.
Second, although the authors argue that Afri-
can populations have more coexisting condi-
tions than other populations, patients with co-
existing conditions may derive greater benefit 
from early treatment.2 Therefore, a new trial in 
Africa might contribute little if other studies show 
a significant benefit from earlier ART.
Finally, the authors acknowledge that millions 
of people do not receive ART as recommended 
by guidelines based on current data. This lack of 
treatment may be due to fiscal constraints and 
lack of capacity in the health system; implemen-
tation research could better identify strategies 
for earlier linkage to treatment or for building 
such capacity. Most important, sustainable fund-
ing for treating people with HIV who we know 
require such treatment for their health is more 
urgently needed than an additional randomized, 
controlled trial on when to start ART in Africa.
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The Authors Reply: Public health decisions and 
the commitment of billions of dollars for health 
programs must be based on the best possible sci-
entific evidence. Yet recommendations concern-
ing when to start ART in the millions of people 
living with HIV are based more on opinion than 
on conclusive evidence; this highlights the need 
for a definitive trial in sub-Saharan Africa, the 
most severely affected region globally. Other 
studies cited by Shah and Grady will provide use-
ful information but not necessarily all the an-
swers required. The START trial focuses predom-
inantly on patients in industrialized countries, 
where the HIV-associated spectrum of disease is 
different from that which predominates in sub-
Saharan Africa. The TEMPRANO trial is limited in 
size and geographic location, and the PROMISE 
trial involves pregnant women.
It is often hazardous in medicine to base 
therapeutic and policy guidance on results of 
single trials, exclusively observational studies, or 
studies designed with a different primary pur-
pose. Implementation science to better guide the 
use of resources and enhance program quality is 
critically important but cannot replace evidence-
based decision making. Decisions about the best 
use of resources are better informed when policy 
options are based on the strongest science.
Kevin M. De Cock, M.D., D.T.M.&H.
Centers for Disease Control and Prevention 
Atlanta, GA
Wafaa M. El-Sadr, M.D., M.P.H.
Columbia University Mailman School of Public Health 
New York, NY
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
DOI: 10.1056/NEJMc1304494
The New England Journal of Medicine 
Downloaded from nejm.org at COLUMBIA UNIV HEALTH SCIENCES LIB on October 9, 2015. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
